Parabilis Medicines Inc. Common Stock (PBLS)
Stock · NASDAQ · Health Care
$22.67as of 10/16/2026
Price chart
Active signals
Resistance level
$28.44
Industry
Biotechnology: Pharmaceutical Preparations
About PBLS
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targete…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 145
- Website
- parabilismed.com
Fundamentals
- 1-day range
- $26.76$29.45
- Market cap
- $4.23B
- P/E (trailing)
- —
- P/E (forward)
- -12.31
- EPS (trailing)
- $-2.04
- Dividend yield
- —
- Beta
- -1.35
- Avg. volume
- 705.9K
52-week range
$24.51$42.49
Next earnings: November 12, 2026 · EPS estimate $-0.38
Forecasts
4 analyst ratings
Buy 91%
Hold 9%
Sell 0%
1-year price forecast
High
$45
+98.5%
Median
$41
+80.9%
Low
$40
+76.4%
Parabilis Medicines Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PBLSParabilis Medicines Inc. Common Stock$22.75▼ 9.65%Market cap $4.23BP/E —$24.51$42.49
- TNGXTango Therapeutics Inc.$22.04▼ 2.91%Market cap $4.19BP/E —$6.69$34.39
- MANEVeradermics Incorporated Common Stock$108.82▼ 5.43%Market cap $4.54BP/E —$32$136.72
- VKTXViking Therapeutics Inc. Common Stock$25.17▼ 8.04%Market cap $3.88BP/E —$25.77$43.15
- GMABGenmab A/S ADS$37▼ 2.17%Market cap $3.83BP/E 26.41$1,512$2,369
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
- EWTXEdgewise Therapeutics Inc. Common Stock$37.19▼ 2.64%Market cap $4.78BP/E —$14.25$48.51
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PBLS Parabilis Medicines Inc. Common Stock | $4.23B | — | $22.75 | ▼ 9.65% | $24.51$42.49 |
| TNGX Tango Therapeutics Inc. | $4.19B | — | $22.04 | ▼ 2.91% | $6.69$34.39 |
| MANE Veradermics Incorporated Common Stock | $4.54B | — | $108.82 | ▼ 5.43% | $32$136.72 |
| VKTX Viking Therapeutics Inc. Common Stock | $3.88B | — | $25.17 | ▼ 8.04% | $25.77$43.15 |
| GMAB Genmab A/S ADS | $3.83B | 26.41 | $37 | ▼ 2.17% | $1,512$2,369 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
| EWTX Edgewise Therapeutics Inc. Common Stock | $4.78B | — | $37.19 | ▼ 2.64% | $14.25$48.51 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trialbenzinga · 10/14/2026
- Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026Yahoo · 9/28/2026
- MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of DirectorsYahoo · 9/23/2026
- Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On ThursdayBenzinga · 9/17/2026
- Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →Acquired
264.9K
Disposed
0
- Tendler Craig · August 22, 2026 · Grant20.3K
- RA CAPITAL MANAGEMENT, L.P. · July 22, 2026 · Buy47.3K @ $29.77
- RA CAPITAL MANAGEMENT, L.P. · July 21, 2026 · Buy37.7K @ $30
- RA CAPITAL MANAGEMENT, L.P. · July 21, 2026 · Buy6.5K @ $29.17
- RA CAPITAL MANAGEMENT, L.P. · July 21, 2026 · Buy21.7K @ $27.96
- RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Buy33.0K @ $27.72
- RA CAPITAL MANAGEMENT, L.P. · July 20, 2026 · Buy98.4K @ $27.13
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial
Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial. Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.